Semax: Limited Stroke Studies and Major Evidence Boundaries

Reviewed for accuracy by the Gorilla Research Insights research team · 2026-07-04

NEUROSCIENCE Semax: Limited Stroke Studies and Major Evidence Boundaries Semax is an ACTH(4-7)-derived peptide studied largely in Russia. Small clinical reports exist, but modern independently replicated evidence for durable patient outcomes remains limited.

What Has Been Studied

An early controlled clinical study evaluated Semax alongside conventional care in 30 people during acute ischemic stroke and compared outcomes with a larger control group. The authors reported faster regression of some neurological deficits, but the study was small, not described as a modern randomized placebo-controlled trial in the indexed abstract, and was published in Russian ^[1]. A later clinical study examined rehabilitation-stage stroke patients and reported changes in plasma BDNF alongside clinical measures ^[2]. Biomarker movement is mechanistically interesting; it is not automatically evidence of durable functional benefit.

The Honest Interpretation

Semax warrants independent, preregistered trials with transparent randomization, masking, prespecified endpoints, and full adverse-event reporting. Existing findings cannot support broad promises about neuroprotection, cognition, mood, or recovery in healthy people.

FAQ

Is Semax FDA approved? No FDA-approved Semax product is established by these sources. Does 10 mg correspond to the cited studies? No. Catalog quantity is not a clinical formulation or regimen.

Primary Sources

• ^[1] Gusev EI et al. Semax in acute hemispheric ischemic stroke . 1997. • ^[2] Gusev EI et al. Semax in different stages of ischemic-stroke rehabilitation . 2018. Educational research summary only; not medical advice. Research materials are not for human use.